Magi Astrology--Financial Astrology

FINANCIAL ASTROLOGY

First Trade Date for Amgen Inc.

Company Name	First Trade Date (yyyy-mm-dd)
Amgen Inc.	1983-06-17

Company Name	Symbol
Amgen Inc.	AMGN
History and Business of Company (this information may include date of incorporation)
Amgen Inc. (AMGN) operates as a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. AMGN manufactures and markets four human therapeutic products: Epogen (Epoetin alfa), Neupogen (Filgrastim), Infergen (Interferon alfacon-1) and Stemgen (Ancestim). Epogen stimulates the production of red blood cells and is marketed in the U.S. for the treatment of anemia associated with chronic renal failure in patients on dialysis. Neupogen selectively stimulates the production of neutrophils, one type of white blood cell. AMGN markets Neupogen in the U.S., countries of the European Union (EU), Canada and Australia for use in decreasing the incidence of infection in patients undergoing myelosuppressive chemotherapy. Also, Neupogen is marketed in most of these countries for use in reducing the duration of neutropenia for patients undergoing myeloablative therapy followed by bone marrow transplantation, for reducing symptoms in patients with severe chronic neutropenia, for supporting peripheral blood progenitor cell transplants and for reducing the recovery time of neutrophils and the duration of fever following chemotherapy treatment in patients being treated for acute myelogenous leukemia. Neupogen is also marketed in the EU, Canada and Australia for use in treating neutropenia in patients infected with HIV receiving antiviral and/or other medications. Infergen is a non-naturally occurring type-1 interferon which stimulates the immune system to fight viral infections and is indicated for the treatment of chronic hepatitis C viral infection. AMGN sells Infergen in the U.S. and Canada. Stemgen stimulates the production, mobilization and maturation of progenitor cells and is indicated for use in support of stem cell transplantation. AMGN markets Stemgen in Canada and Australia. AMGN focuses its research and development efforts on human therapeutics in the areas of nephrology, cancer, inflammation and neurology and metabolism. AMGN has research facilities in the U.S. and Canada and staff in the U.S., the EU, Canada, Australia, Japan and the People's Republic of China. AMGN operates commercial manufacturing facilities located in the U.S., Puerto Rico and The Netherlands. A sales and marketing force is maintained in the U.S., EU, Canada, Australia, New Zealand and the People's Republic of China. Also, AMGN has licensing agreements to market its products in other areas. Product sales were $3,202.2 million in 2000, an increase of $159.4 million or 5% over the prior year. INCORPORATED in Delaware Oct. 31, 1986, to merge, on a share-for- share basis on Jan. 27, 1987, a company of the same name (Predecessor). Predecessor was incorporated in California Apr. 8, 1980, as Applied Molecular Genetics, Inc.; name changed to Amgen Inc. May 4, 1983. OFFICE- One Amgen Center Drive, Thousand Oaks, CA, USA 91320-1799 (Tel.: 805-447-1000). Fax - 805-447-1010. WEBSITE-http://www.amgen.com.

IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.